Post-marketing surveillance of prophylactic mefloquine (Lariam®) use in pregnancy

Bart Vanhauwere, Hilal D Maradit Kremers, Lydia Kerr

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

The purpose of this study was to evaluate the teratogenic potential of mefloquine (Lariam®) in pregnancy, based on the Roche International Spontaneous Reporting System. Lariam® is an anti-malarial drug used both in prophylaxis and treatment of malaria. Teratogenic effects were observed in animals but data from humans are lacking. Women of childbearing potential are currently advised to take contraceptive precautions up to three months after the last dose. The study included 1,627 spontaneous reports of women exposed to Lariam® before or during pregnancy, which were received by Roche worldwide since introduction on the market. The data were analyzed considering pregnancy and fetal outcome and type of congenital malformations. The birth prevalence of congenital malformations in women exposed to Lariam® is estimated to be 4% and is not different from the prevalence observed in the general population. In addition, the congenital malformations observed with Lariam® exposure do not show any specific pattern. The data from our study suggest that the teratogenicity, which was observed in animals at high doses, cannot be applied to humans.

Original languageEnglish (US)
Pages (from-to)17-21
Number of pages5
JournalAmerican Journal of Tropical Medicine and Hygiene
Volume58
Issue number1
StatePublished - 1998
Externally publishedYes

Fingerprint

Mefloquine
Marketing
Pregnancy
Antimalarials
Pregnancy Outcome
Contraceptive Agents
Malaria
Parturition
Pharmaceutical Preparations
Population

ASJC Scopus subject areas

  • Parasitology
  • Infectious Diseases

Cite this

Post-marketing surveillance of prophylactic mefloquine (Lariam®) use in pregnancy. / Vanhauwere, Bart; Maradit Kremers, Hilal D; Kerr, Lydia.

In: American Journal of Tropical Medicine and Hygiene, Vol. 58, No. 1, 1998, p. 17-21.

Research output: Contribution to journalArticle

@article{492446b478c147c9b4d1eb88ce96e745,
title = "Post-marketing surveillance of prophylactic mefloquine (Lariam{\circledR}) use in pregnancy",
abstract = "The purpose of this study was to evaluate the teratogenic potential of mefloquine (Lariam{\circledR}) in pregnancy, based on the Roche International Spontaneous Reporting System. Lariam{\circledR} is an anti-malarial drug used both in prophylaxis and treatment of malaria. Teratogenic effects were observed in animals but data from humans are lacking. Women of childbearing potential are currently advised to take contraceptive precautions up to three months after the last dose. The study included 1,627 spontaneous reports of women exposed to Lariam{\circledR} before or during pregnancy, which were received by Roche worldwide since introduction on the market. The data were analyzed considering pregnancy and fetal outcome and type of congenital malformations. The birth prevalence of congenital malformations in women exposed to Lariam{\circledR} is estimated to be 4{\%} and is not different from the prevalence observed in the general population. In addition, the congenital malformations observed with Lariam{\circledR} exposure do not show any specific pattern. The data from our study suggest that the teratogenicity, which was observed in animals at high doses, cannot be applied to humans.",
author = "Bart Vanhauwere and {Maradit Kremers}, {Hilal D} and Lydia Kerr",
year = "1998",
language = "English (US)",
volume = "58",
pages = "17--21",
journal = "American Journal of Tropical Medicine and Hygiene",
issn = "0002-9637",
publisher = "American Society of Tropical Medicine and Hygiene",
number = "1",

}

TY - JOUR

T1 - Post-marketing surveillance of prophylactic mefloquine (Lariam®) use in pregnancy

AU - Vanhauwere, Bart

AU - Maradit Kremers, Hilal D

AU - Kerr, Lydia

PY - 1998

Y1 - 1998

N2 - The purpose of this study was to evaluate the teratogenic potential of mefloquine (Lariam®) in pregnancy, based on the Roche International Spontaneous Reporting System. Lariam® is an anti-malarial drug used both in prophylaxis and treatment of malaria. Teratogenic effects were observed in animals but data from humans are lacking. Women of childbearing potential are currently advised to take contraceptive precautions up to three months after the last dose. The study included 1,627 spontaneous reports of women exposed to Lariam® before or during pregnancy, which were received by Roche worldwide since introduction on the market. The data were analyzed considering pregnancy and fetal outcome and type of congenital malformations. The birth prevalence of congenital malformations in women exposed to Lariam® is estimated to be 4% and is not different from the prevalence observed in the general population. In addition, the congenital malformations observed with Lariam® exposure do not show any specific pattern. The data from our study suggest that the teratogenicity, which was observed in animals at high doses, cannot be applied to humans.

AB - The purpose of this study was to evaluate the teratogenic potential of mefloquine (Lariam®) in pregnancy, based on the Roche International Spontaneous Reporting System. Lariam® is an anti-malarial drug used both in prophylaxis and treatment of malaria. Teratogenic effects were observed in animals but data from humans are lacking. Women of childbearing potential are currently advised to take contraceptive precautions up to three months after the last dose. The study included 1,627 spontaneous reports of women exposed to Lariam® before or during pregnancy, which were received by Roche worldwide since introduction on the market. The data were analyzed considering pregnancy and fetal outcome and type of congenital malformations. The birth prevalence of congenital malformations in women exposed to Lariam® is estimated to be 4% and is not different from the prevalence observed in the general population. In addition, the congenital malformations observed with Lariam® exposure do not show any specific pattern. The data from our study suggest that the teratogenicity, which was observed in animals at high doses, cannot be applied to humans.

UR - http://www.scopus.com/inward/record.url?scp=0031943736&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031943736&partnerID=8YFLogxK

M3 - Article

C2 - 9452285

AN - SCOPUS:0031943736

VL - 58

SP - 17

EP - 21

JO - American Journal of Tropical Medicine and Hygiene

JF - American Journal of Tropical Medicine and Hygiene

SN - 0002-9637

IS - 1

ER -